TNBC App Note Summary
- Available TNBC PDX models and cell lines
- Standard of Care Data with TNBC Models
- Summary of BRCA1, BRCA2, and TP53 Mutations in TNBC Models
- Bioluminescent Analysis of Bone and Brain Metastasis
- Evaluation of TNBC models in Immunotherapy
Download our free TNBC App note to learn more.
Approximately 10% to 20% of breast cancers are triple negative, meaning that they do not express ER or PRs, and do not have an excess of the HER2 protein on the cancer cell surfaces. These so called triple negative breast cancers (TNBC) are difficult to treat as they are insensitive to some of the most effective targeted therapies available for breast cancer, leaving patients with an associated poor prognosis.
HuPrime TNBC PDX Models
CrownBio has developed several TNBC patient derived models and validated them for in vivo studies. As expected ER- and HER2- cancer models BR1282 and BR1458 showed resistant to treatment with targeted agents tamoxifen and Herceptin. With platinum agents emerging as drugs of interest in TNBC, cisplatin treatment has also been trialed, with sensitivity to this agent varying across the models tested. The microtubule inhibitors eribulin (which as Halaven® is approved by the FDA for the treatment of metastatic breast cancer) and vinorelbine have also been utilized in our PDX models, with all models tested proving sensitive to these agents.